TCM
PCRX icon

Tygh Capital Management’s Pacira BioSciences PCRX Stock Holding History

Tygh Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$10.9M Buy
181,055
+26,614
+17% +$1.47M 1.39% 29
2021
Q3 		$8.65M Buy
154,441
+2,109
+1% +$122K 1.17% 40
2021
Q2 		$9.24M Buy
152,332
+57,725
+61% +$3.65M 1.26% 34
2021
Q1 		$6.63M Sell
94,607
-72,610
-43% -$5.19M 0.94% 47
2020
Q4 		$10M Buy
167,217
+27,882
+20% +$1.63M 1.56% 22
2020
Q3 		$8.38M Buy
139,335
+62,160
+81% +$3.61M 1.59% 22
2020
Q2 		$4.05M Buy
+77,175
New +$3.23M 0.84% 52
2019
Q1 		– Sell
-88,501
Closed -$3.81M – 87
2018
Q4 		$3.81M Buy
+88,501
New +$4.13M 0.8% 59
2018
Q1 		– Sell
-91,161
Closed -$4.16M – 102
2017
Q4 		$4.16M Buy
+91,161
New +$3.61M 0.78% 61
2017
Q3 		– Sell
-58,710
Closed -$2.8M – 96
2017
Q2 		$2.8M Sell
58,710
-51,410
-47% -$2.39M 0.63% 76
2017
Q1 		$5.02M Buy
+110,120
New +$4.76M 1.17% 39
2016
Q2 		– Sell
-32,795
Closed -$1.74M – 94
2016
Q1 		$1.74M Sell
32,795
-43,844
-57% -$2.56M 0.51% 80
2015
Q4 		$5.88M Buy
+76,639
New +$4.34M 1.65% 16
2015
Q3 		– Sell
-36,987
Closed -$2.62M – 104
2015
Q2 		$2.62M Sell
36,987
-33,821
-48% -$2.66M 0.47% 85
2015
Q1 		$6.29M Buy
70,808
+13,381
+23% +$1.36M 1.16% 31
2014
Q4 		$5.09M Buy
57,427
+44,356
+339% +$4.2M 0.99% 46
2014
Q3 		$1.27M Buy
+13,071
New +$1.27M 0.28% 97
2013
Q4 		– Sell
-125,118
Closed -$6.01M – 128
2013
Q3 		$6.01M Sell
125,118
-134,994
-52% -$4.92M 1.35% 23
2013
Q2 		$7.54M Buy
+260,112
New +$7.52M 1.67% 11

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Tygh Capital Management's PCRX Position: Q4 2021 in Review

Tygh Capital Management increased its Pacira BioSciences (PCRX) stake by 17% in Q4 2021, buying an estimated $1.47M and bringing the position to 181,055 shares worth $10.9M. The position accounts for 1.39% of the portfolio, ranked #29.

Tygh Capital Management first reported a position in PCRX in Q2 2013 and has held it in 19 quarters since. 276 funds tracked by Wall St. Rank hold PCRX as of Q4 2021.

  • Tygh Capital Management held 181,055 shares of Pacira BioSciences worth $10.9M as of Q4 2021.
  • Tygh Capital Management bought 26,614 Pacira BioSciences shares in Q4 2021, an estimated $1.47M.
  • Pacira BioSciences made up 1.39% of Tygh Capital Management's portfolio in Q4 2021, its #29 holding.
  • Tygh Capital Management first reported a position in Pacira BioSciences in Q2 2013 and has held it in 19 quarters since.
  • 276 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2021.

Based on Tygh Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.